Vanguard Group Inc. Decreases Position in Teva Pharmaceutical Industries Limited (TEVA)

Vanguard Group Inc. cut its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,802,632 shares of the company’s stock after selling 47,169 shares during the period. Vanguard Group Inc. owned about 0.18% of Teva Pharmaceutical Industries Limited worth $57,846,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Alliancebernstein L.P. boosted its position in Teva Pharmaceutical Industries Limited by 7.3% in the first quarter. Alliancebernstein L.P. now owns 8,617,143 shares of the company’s stock valued at $276,524,000 after buying an additional 587,286 shares during the period. State of Wisconsin Investment Board boosted its position in Teva Pharmaceutical Industries Limited by 0.8% in the first quarter. State of Wisconsin Investment Board now owns 1,952,150 shares of the company’s stock valued at $62,644,000 after buying an additional 15,140 shares during the period. American Century Companies Inc. boosted its position in Teva Pharmaceutical Industries Limited by 7.2% in the first quarter. American Century Companies Inc. now owns 1,791,707 shares of the company’s stock valued at $57,496,000 after buying an additional 120,041 shares during the period. AGF Investments Inc. boosted its position in Teva Pharmaceutical Industries Limited by 5.7% in the first quarter. AGF Investments Inc. now owns 1,549,244 shares of the company’s stock valued at $49,673,000 after buying an additional 84,133 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. boosted its position in Teva Pharmaceutical Industries Limited by 405,409.9% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,435,505 shares of the company’s stock valued at $46,065,000 after buying an additional 1,435,151 shares during the period. Hedge funds and other institutional investors own 56.04% of the company’s stock.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 17.30 on Friday. Teva Pharmaceutical Industries Limited has a 12 month low of $16.81 and a 12 month high of $53.96. The firm’s 50-day moving average is $27.46 and its 200 day moving average is $30.98. The company’s market capitalization is $17.58 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.25 earnings per share. Equities research analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be issued a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.97%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently -18.95%.

ILLEGAL ACTIVITY WARNING: “Vanguard Group Inc. Decreases Position in Teva Pharmaceutical Industries Limited (TEVA)” was originally reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.com-unik.info/2017/08/19/vanguard-group-inc-sells-47169-shares-of-teva-pharmaceutical-industries-limited-teva-updated.html.

TEVA has been the subject of a number of analyst reports. Vetr raised shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating and set a $32.27 target price for the company in a report on Wednesday, June 28th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $38.00 target price (down previously from $42.00) on shares of Teva Pharmaceutical Industries Limited in a report on Monday, May 15th. Piper Jaffray Companies reaffirmed a “neutral” rating and set a $23.00 target price (down previously from $28.00) on shares of Teva Pharmaceutical Industries Limited in a report on Friday, August 4th. Wells Fargo & Company reaffirmed a “market perform” rating on shares of Teva Pharmaceutical Industries Limited in a report on Saturday, April 29th. Finally, Oppenheimer Holdings, Inc. lowered shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and set a $41.00 target price for the company. in a report on Thursday, August 3rd. Three equities research analysts have rated the stock with a sell rating, twenty have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $36.73.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit